New Online Education Offerings

Uterine mesenchymal neoplasms: new and evolving entities

Cervical Cancer Survivorship: A Patient's Perspective

Palliative Care in Disaster and Conflict Settings

Home > Educational Webinars

Recently Recorded

Uterine mesenchymal neoplasms: new and evolving entities

In this session, we will review new and evolving uterine mesenchymal entities as well as biomarker and molecular assays to aid in these diagnoses. Additionally, appropriate diagnostic terminology will be covered in the absence of accessible immunohistochemistry and molecular testing.

This webinar is complimentary for IGCS members.

Brooke Howitt, MD
Associate Professor of Pathology
Stanford University School of Medicine

 Adrian Suarez, MD
Surgical Pathology Director
The Ohio State University Wexner Medical Center

Palliative Care in Disaster and Conflict Settings

Political and ethnic conflict, and geological and climatic disasters, result in suffering on a massive scale, particularly in low- and middle-income countries with fragile health care systems. Palliative care, defined most often as a response to physical, psychological, social, or spiritual suffering of those with “life-limiting illness,” is crucial for those with such illnesses in humanitarian settings. But those without life-limiting illnesses also suffer severely, due, for example, to gender-based violence or to witnessing and fleeing from extreme violence. This webinar will explore how, in humanitarian settings, palliative care can and should be true to its mission of responding to suffering without the constraint of focusing only on those with life-limiting illnesses.

This webinar is complimentary for IGCS members.

Eric L. Krakauer, MD, PhD
Director, Program in Global Palliative Care
Associate Professor of Medicine
Associate Professor of Global Health & Social Medicine
Harvard Medical School

Annekathryn “AK” Goodman, MD, MS, MPH
Professor of Obstetrics, Gynecology and Reproductive Biology
Harvard Medical School

Nahla Gafer, MD
Clinical Oncologist & Head Palliative Care Unit
Khartoum Oncology Hospital
Director, Palliative Care Continuous Education
Comboni College of Science and Technology

 Peter Grant, MD
Assoc Professor, University of Melbourne
Gynaecological Oncologist, Western Health, Melbourne

 Anisa Mburu, MD
Gynecologic Oncologist
Aga Khan Hospital and International Cancer Institute

The Evolving Treatment Landscape for The Management of Endometrial Cancer

IGCS and Eisai welcomes gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies to view the first presentation from the An Evolving Frontier - Understanding Novel Treatment Options for The Management of Advanced Stage or Recurrent Endometrial Cancers Industry Supported Symposium presented at the IGCS 2023 Annual Global Meeting in Seoul, Korea.

Part 1: The Evolving Treatment Landscape for The Management of Endometrial Cancer
Released February 2024


Ramez N. Eskander, MD
UC San Diego School of Medicine

Part 2: Immunotherapy After Immunotherapy, What Are The Opportunities for Immune Check-Point Inhibition Re-challenge and The Role of Pembrolizumab/Lenvatinib
Released June 2024

Stephanie Lheureux, MD, PhD
Princess Margaret Cancer Centre

Eisai have sponsored this initiative with IGCS and had no input into or influence over the content.

Cervical Cancer Survivorship:
A Patient's Perspective

In this IGCS Advances & Updates special presentation, Linda Ryan, a metastatic recurrent cervical cancer survivor and patient research advocate shares her story and experience with clinical trials. Linda is joined by her gynecologic oncologist, Dr. Shannon Westin, a professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center in Houston, Texas. Listen to Linda and Dr. Westin as they discuss recent approval and therapeutic options for patients with recurrent cervical cancer.

Emerging Data in platinum resistance advanced ovarian cancer

Lainie P. Martin, MD
Leader, Gynecology/Oncology Program
Associate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
Associate Professor of Obstetrics and Gynecology
University of Pennsylvania Perelman School of Medicine

David O’Malley, MD  
Ohio State University Comprehensive Cancer Center-James Cancer Hospital &
Solove Research Institute Professor
Director, Division of Gynecologic Oncology
Co-Director, Gyn Oncology Phase I Program

Selinexor in Maintenance Therapy After Systemic Therapy for Patients with p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma: XPORT-042 - Trial in Progress

Robert Coleman, MD, FACOG, FACS
Chief Medical Officer
Vaniam Group

Floor Backes, MD

Director of Clincial Research and Fellowship Director for the Division of Gynecologic Oncology
The Ohio State University Wexner Medical Center
James Comprehensive Cancer Center

Available as a Podcast!
Would you rather listen to this recording? Listen on Education360 Learning Portal or the streaming services below!

Immunotherapy and its impact on overall survival in patients with recurrent endometrial cancer

Matthew A. Powell, MD
Professor, Div Gyn Oncology
Chair Uterine Corpus Committee
National Cancer Institute sponsored NRG Oncology
Washington University School of Medicine

R. Wendel Naumann, M.D.
Director of Gynecologic Oncology Research
Associate Medical Director of Clinical Trials
Levine Cancer Institute – Hall Gynecologic Oncology Center

Newly Opened Phase 3 Study for Low Grade Serous Ovarian Cancer

Rachel Grisham, MD
Section Head Ovarian Cancer
Director, Gynecologic Medical OncologyMemorial Sloan Kettering Cancer Center

Susana Banerjee, MBBS, MA, PhD, FRCP
Consultant Medical Oncologist
Research Lead Gynaecology Unit
The Royal Marsden
Professor in Women’s Cancers,Institute of Cancer Research, London

Dr. Rachel Grisham and Dr. Susana Banerjee discussed details about a potential clinical trial for your patients. The RAMP 301 trial is evaluating the novel combination of avutometinib + defactinib versus investigator’s choice of therapy in patients with recurrent low grade serous ovarian cancer.

Visit Education360 Learning Portal for more.

Leave a Reply